Back to discover

Protein / target

Nuclear receptor subfamily 1 group D member 1

Encoded byNR1D1P20393Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
Structure with Ligand
1
Research papers

Protein at a glance

Biological role

Sequence-specific double-stranded DNA binding

Strongest disease association

Peripheral resistance to thyroid hormones

Via encoding gene NR1D1 · Genetic evidence · score 0.63

Research activity

Emerging research

1 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Transcriptional repressor which coordinates circadian rhythm and metabolic pathways in a heme-dependent manner.

View complete UniProt function annotation

Transcriptional repressor which coordinates circadian rhythm and metabolic pathways in a heme-dependent manner. Integral component of the complex transcription machinery that governs circadian rhythmicity and forms a critical negative limb of the circadian clock by directly repressing the expression of core clock components BMAL1, CLOCK and CRY1. Also regulates genes involved in metabolic functions, including lipid and bile acid metabolism, adipogenesis, gluconeogenesis and the macrophage inflammatory response. Acts as a receptor for heme which stimulates its interaction with the NCOR1/HDAC3 corepressor complex, enhancing transcriptional repression. Recognizes two classes of DNA response elements within the promoter of its target genes and can bind to DNA as either monomers or homodimers, depending on the nature of the response element. Binds as a monomer to a response element composed of the consensus half-site motif 5'-[A/G]GGTCA-3' preceded by an A/T-rich 5' sequence (RevRE), or as a homodimer to a direct repeat of the core motif spaced by two nucleotides (RevDR-2). Acts as a potent competitive repressor of ROR alpha (RORA) function and regulates the levels of its ligand heme by repressing the expression of PPARGC1A, a potent inducer of heme synthesis. Regulates lipid metabolism by repressing the expression of APOC3 and by influencing the activity of sterol response element binding proteins (SREBPs); represses INSIG2 which interferes with the proteolytic activation of SREBPs which in turn govern the rhythmic expression of enzymes with key functions in sterol and fatty acid synthesis. Regulates gluconeogenesis via repression of G6PC1 and PEPCK and adipocyte differentiation via repression of PPARG. Regulates glucagon release in pancreatic alpha-cells via the AMPK-NAMPT-SIRT1 pathway and the proliferation, glucose-induced insulin secretion and expression of key lipogenic genes in pancreatic-beta cells. Positively regulates bile acid synthesis by increasing hepatic expression of CYP7A1 via repression of NR0B2 and NFIL3 which are negative regulators of CYP7A1. Modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy; controls mitochondrial biogenesis and respiration by interfering with the STK11-PRKAA1/2-SIRT1-PPARGC1A signaling pathway. Represses the expression of SERPINE1/PAI1, an important modulator of cardiovascular disease and the expression of inflammatory cytokines and chemokines in macrophages. Represses gene expression at a distance in macrophages by inhibiting the transcription of enhancer-derived RNAs (eRNAs). Plays a role in the circadian regulation of body temperature and negatively regulates thermogenic transcriptional programs in brown adipose tissue (BAT); imposes a circadian oscillation in BAT activity, increasing body temperature when awake and depressing thermogenesis during sleep. In concert with NR2E3, regulates transcriptional networks critical for photoreceptor development and function. In addition to its activity as a repressor, can also act as a transcriptional activator. In the ovarian granulosa cells acts as a transcriptional activator of STAR which plays a role in steroid biosynthesis. In collaboration with SP1, activates GJA1 transcription in a heme-independent manner. Represses the transcription of CYP2B10, CYP4A10 and CYP4A14 (By similarity). Represses the transcription of CES2 (By similarity). Represses and regulates the circadian expression of TSHB in a NCOR1-dependent manner (By similarity). Negatively regulates the protein stability of NR3C1 and influences the time-dependent subcellular distribution of NR3C1, thereby affecting its transcriptional regulatory activity (By similarity). Plays a critical role in the circadian control of neutrophilic inflammation in the lung; under resting, non-stress conditions, acts as a rhythmic repressor to limit inflammatory activity whereas in the presence of inflammatory triggers undergoes ubiquitin-mediated degradation thereby relieving inhibition of the inflammatory response (By similarity). Plays a key role in the circadian regulation of microglial activation and neuroinflammation; suppresses microglial activation through the NF-kappaB pathway in the central nervous system (By similarity). Plays a role in the regulation of the diurnal rhythms of lipid and protein metabolism in the skeletal muscle via transcriptional repression of genes controlling lipid and amino acid metabolism in the muscle (By similarity)

Subcellular location

NucleusCytoplasmCell projection, dendriteCell projection, dendritic spine
Domains and Gene Ontology detail (53)

Domains & features

NR LBD

Gene Ontology

  • Cchromatin
  • Ccytoplasm
  • Cdendrite
  • Cdendritic spine
  • Cnuclear body
  • Cnucleoplasm
  • Cnucleus
  • FDNA-binding transcription factor activity, RNA polymerase II-specific
  • FDNA-binding transcription repressor activity, RNA polymerase II-specific
  • FE-box binding
  • Fheme binding
  • Fnuclear receptor activity

614 aa · 67 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Lipid & lipoprotein metabolismUniProt · GONuclear receptor signallingGOImmune signallingUniProt · GOTranscriptional regulationUniProt · GO
View supporting evidence

Lipid & lipoprotein metabolism

  • ·Transcriptional repressor which coordinates circadian rhythm and metabolic pathways in a…
  • ·cholesterol homeostasis
  • ·regulation of lipid metabolic process

Nuclear receptor signalling

  • ·nuclear receptor activity

Immune signalling

  • ·Transcriptional repressor which coordinates circadian rhythm and metabolic pathways in a…
  • ·cellular response to interleukin-1
  • ·negative regulation of inflammatory response
  • ·negative regulation of neuroinflammatory response

Transcriptional regulation

  • ·Transcriptional repressor which coordinates circadian rhythm and metabolic pathways in a…
  • ·DNA-binding transcription factor activity, RNA polymerase II-specific
  • ·DNA-binding transcription repressor activity, RNA polymerase II-specific
  • ·RNA polymerase II cis-regulatory region sequence-specific DNA binding

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene NR1D1

Gene-level evidence surfaced through the gene NR1D1that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Peripheral resistance to thyroid hormones
0.63Moderately supported

Genetic evidence dominant · Open Targets 0.38

Asthma
0.32Limited support

Genetic evidence dominant · Open Targets 0.19

Peptic ulcer disease
0.30Limited support

Genetic evidence dominant · Open Targets 0.18

Genetic Diseases, Inborn
0.24Preliminary

Genetic evidence dominant · Open Targets 0.15

Neurodegenerative Diseases
0.19Preliminary

Pathway evidence dominant · Open Targets 0.28 · no direct causal or clinical evidence

View evidence synthesis (5)
Peripheral resistance to thyroid hormonesModerately supported
0.63
agreement 0.510.75
Genetic100%

Open Targets aggregate 0.38 · 1 independent evidence family

AsthmaLimited support
0.32
agreement 0.180.46
Genetic91%Literature9%

Open Targets aggregate 0.19 · 2 independent evidence families

Peptic ulcer diseaseLimited support
0.30
agreement 0.180.42
Genetic100%

Open Targets aggregate 0.18 · 1 independent evidence family

Genetic Diseases, InbornPreliminary
0.24
agreement 0.120.36
Genetic100%

Open Targets aggregate 0.15 · 1 independent evidence family

Neurodegenerative DiseasesPreliminary
0.19
agreement 0.010.37
Pathway96%Literature4%

Open Targets aggregate 0.28 · 2 independent evidence families · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Peripheral resistance to thyroid hormones0.38
Neurodegenerative Diseases0.28
Asthma0.19
Peptic ulcer disease0.18
Genetic Diseases, Inborn0.15
Neoplasms0.10
Stomach Neoplasms0.10
Breast Neoplasms0.09

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand and high-quality ligand) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (6)
SM · Structure with LigandSM · High-Quality LigandSM · Druggable FamilyPR · UniProt UbiquitinationPR · Database UbiquitinationPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.